Table 2.

Use of oral anticoagulants and APA after ischaemic stroke and associations with 1-year mortality, recurrent stroke and major bleeding for patients with atrial fibrillation and carotid disease, after propensity score matching

Medication use	Participants, n	Deaths, %	HR (95% CI) for mortality	Recurrent stroke, %	HR (95% CI) for stroke	Major bleeding, %	HR (95% CI) for major bleeding
NOACs without APA	1123	11.0	Ref	44.9	Ref	19.4	Ref
Warfarin without APA	1123	13.5	1.19 (0.93, 1.52)	41.9	0.90 (0.79, 1.02)	25.6	1.34 (1.12, 1.60)
NOACs without APA	1112	11.4	Ref	50.0	Ref	20.7	Ref
Warfarin plus APA	1112	17.0	1.51 (1.20, 1.89)	47.9	0.98 (0.87, 1.11)	31.5	1.66 (1.40, 1.96)
NOACs without APA	1269	12.1	Ref	48.7	Ref	18.5	Ref
NOAC plus APA	1269	13.2	1.12 (0.90, 1.40)	46.6	1.01 (0.90, 1.13)	21.9	1.27 (1.07, 1.51)
Warfarin without APA	1089	13.7	Ref	41.5	Ref	28.1	Ref
Warfarin plus APA	1089	15.4	1.17 (0.94, 1.47)	42.2	1.05 (0.92, 1.20)	27.3	0.98 (0.84, 1.15)

HR, hazard ratio; CI, confidence interval; NOAC, non-vitamin K antagonist oral anticoagulants; Ref, reference group